Ticker

No recent analyst price targets found for SBFM.

Latest News for SBFM

Health Canada Approves Sunshine Biopharma's Atenolol for Treating and Managing Cardiovascular Conditions

FORT LAUDERDALE, FL / ACCESS Newswire / August 31, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its Atenolol tablets of 25mg, 50mg and 100mg for the Canadian market. Atenolol is the generic equivalent of the brand name, Tenormin®.

Accesswire • Aug 31, 2026
Sunshine Biopharma Reports In Vivo Tumor Suppression with K1.1 mRNA and Advances Novel mRNA-Cancer Vaccine Strategy for Lung Cancer

K1.1 mRNA demonstrated tumor-suppressing activity as a single agent in multiple in vivo hepatocellular carcinoma models Program targets a tumor suppressor frequently mutated in difficult-to-treat lung, pancreatic and liver cancers Next phase will combine K1.1 mRNA with a cancer vaccine in NSCLC with the goal of converting "cold" tumors into "hot" tumors FORT LAUDERDALE, FL / ACCESS Newswire / August 26, 2026 /…

Accesswire • Aug 26, 2026
Sunshine Biopharma Receives Canadian Regulatory Approval for Enalapril, Expanding Into $25.94 Billion Global Anti-Hypertensive Drug Market

Global anti-hypertensive drug market projected to reach $37.24 billion by 2034 Enalapril is a widely prescribed ACE inhibitor used to treat hypertension, heart failure and left ventricular dysfunction Sunshine Biopharma expects Enalapril tablets in four dosage strengths to begin shipping to Canadian pharmacies by year-end 2026 FORT LAUDERDALE, FL / ACCESS Newswire / August 19, 2026 / Sunshine Biopharma Inc.…

Accesswire • Aug 19, 2026
Sunshine Biopharma Launches Amoxicillin in Canada and Begins Pharmacy Shipments, Targeting an Estimated $4.9 Billion Global Market

Sunshine Biopharma's Amoxicillin now shipping to Canadian pharmacies in multiple dosages and strengths Launch expands Sunshine Biopharma's growing portfolio of essential prescription medications Global Amoxicillin market projected to reach approximately $6.4 billion by 2031 FORT LAUDERDALE, FL / ACCESS Newswire / August 7, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company…

Accesswire • Aug 7, 2026
Sunshine Biopharma Enters the $2.8 Billion Global Dienogest Market with Canadian Regulatory Approval

Dienogest is first-line therapy for pelvic pain associate with endometriosis The endometriosis treatment market is projected to reach $5.2 billion by 2034 FORT LAUDERDALE, FL / ACCESS Newswire / August 4, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic…

Accesswire • Aug 4, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for SBFM.

House Trades Disclosures

NameTransaction DateTypeAssetAmountLink

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top